This study was designed to examine the integrated metabolism of apolipoprotein B (apo B) in very low density lipoproteins
LDL in normal subjects, in obese subjects, and in a group of patients with coronary heart disease (CHD). Recent reports from our laboratory have shown that obese subjects (4) have increased production rates of LDL, and the same is true for at least some patients with CHD (5) . The current work extends these previous investigations to examine mechanisms responsible for enhanced production of LDL in both types of patients. It has employed techniques for the evaluation of apo B metabolism described in the preceding article (6) .
Methods Patients 14 patients were studied in the Special Diagnostic and Treatment Unit of the Veterans Administration Medical Center, San Diego, California. These included five normal subjects, four obese patients, and five patients with premature CHD. The age, sex, and body habitus at the time of the metabolic studies, and diagnosis of each patient are presented in Table I .
The five normal subjects were all men. None had a history of CHD. Their ages averaged 57±1 yr (from 52 to 63 yr), and their weights were 80±1 kg (I 12±2% ideal weight [IW] [7] ). Three subjects (nos. 2, 3, and 5) were smokers, but none had hypertension, diabetes mellitus, liver disease, or renal disease. None were taking digitalis, diuretics, or fl-adrenergic blocking agents. Electrocardiograms were normal, as were their cardiovascular systems by physical examination. None were or had been on lipid-lowering diets or drugs. Plasma lipid and lipoprotein levels were below the 95th percentile for the corresponding age and sex group according to data of the Lipid Research Clinics Program Prevalence Study (8, 9) .
The four obese patients were 54±5 yr old (range 41 to 64 yr); one (no. 8) was a woman. Their mean body weight was 96±12 kg. Each subject had a weight exceeding 125% of their ideal weight (assuming a medium body frame [7] ). The percentage of IWs averaged 146±15% (range 127-189%). None had xanthomata, xanthalasma, or fasting or 2-h postprandial hyperglycemia. Three subjects (nos. 6, 7, and 8) were smokers. None had a history of hypertension, myocardial infarction, or hepatic or renal disease, and their electrocardiograms and cardiovascular systems were normal by physical examination. None had been on any special diet or lipid-lowering drugs. All but one (no. 8) had plasma lipid and lipoprotein levels below the 95th percentile for their age and sex (8, 9) (Table II) .
The five patients with CHD were 59±2 yr old (52-62 yr), and their ages at the clinical onset of CHD averaged 50±3 yr (from 42 to 60 yr). Mean body weight was 73±2 kg (mean % IW = 109±3%). In three patients (nos. 10, 12, and 13), coronary artery bypass grafting was done at the age of 61, 50, and 60 yr, respectively. Patient I I had a myocardial infarction proven by electrocardiogram and enzyme changes at age 49 yr. Patient 14 developed angina pectoris at age 42 yr, and coronary angiogram at that age revealed advanced coronary artherosclerosis. Several patients had bruits over carotid and femoral arteries, but none had heart failure. Also, none had xanthomata, xanthalasma, fasting or 2-h postprandial hyperglycemia. Two patients (nos. 11 and 14) were taking propranolol and another (no. 12) metoprolol for ischemic heart disease; three (nos. 11, 12, and 13) were on diuretics. All patients were normotensive at the time of the study. Most were smokers before their first myocardial infarction but had 66  60  110  11  61  M  80  70  114  12  52  M  70  64  110  13  61  M  75  76  99  14  57  M  74  65  113  Mean±SEM  59±2  73±2  67±3  109±3 stopped or greatly reduced smoking after their attacks. None were on lipid-lowering drugs at the time of study. Patient 14 previously had been on cholestyramine and clofibrate, but stopped these drugs 6 mo before admission. The patients' dietary habits before admission were reviewed carefully. One patient (no. 12) claimed that he attempted to Normal subjects  1  161±5  72±6  101±6  47±1  2  169±4  106±3  123±4  30±1  3  195±7  148±8  135±4  34±2  4  245±3  133±19  161±4  61±1  5  273±6  200±5  184±7  52±2  Mean±SEM  208±19  132±19  141±13  45±5   Obese subjects  6  207±7  170±21  125±5  51±3  7  238±4  130±5  176±4  41±2  8  309±10  207±11  218±8  55±3  9  269±4  214±10  191±6  36±2  Mean±SEM  255±19  180±17  177±17  46±4   CHD patients  10  191±7  225±24  102±9  32±3  11  194±7  109±5  130±6  35±2  12  210±4  168±14  129±7  41±1  13  211±7  125±12  121±13  45±4  14  332±5  167±5  231±5  61±2  Mean±SEM  228±26  159±22  143±23  43±5 * Mean±SD of 18 samples during VLDL turnover study.
decrease his cholesterol intake after heart surgery. None of the others were on special diets: most had been told that dietary change was not necessary because of normal plasma cholesterol. All but one (no. 14) had plasma lipid and lipoprotein levels below the 95th percentile for their age and sex (8, 9) . The investigations were approved by the Institutional Review Board, and all patients gave informed consent for the study.
Experimental design
During hospitalization, turnover rates of VLDL-apo B (VLDL-B), IDL-B, LDL-B, and VLDL-triglycerides (TG) were estimated. Patients were hospitalized on the metabolic ward for 10 d to 2 wk before initiation of turnover studies. During this period they were fed a diet of mixed solid food and liquid formula containing 40% of calories as fat. The basic composition and pattern of this diet have been described in detail previously (10) . Three liquid meals and one meal of solid food were given each day. Calories were divided approximately equally between feedings. The liquid meals were given at 8:30 a.m., 1:00 p.m., and 7:00 p.m. They contained 15% of calories as milk protein, 45% as dextrose, and 40% as fat, mostly as lard. This liquid diet was prepared by Hospital Diet Products, Organon Inc., Buena Park, CA. One meal of solid food was given at 1 1:00 a.m., and it contained dry cereal (corn flakes), nonfat bread, skim milk, added fat, and sugar for coffee. Fat comprised '40% of calories in the solid food meal. Cholesterol intakes ranged from 85 to 253 mg/d. The ratio of polyunsaturated to saturated fats was 0.2. Vitamin and mineral supplements were given daily. Each patient was weighed daily, and caloric intake was adjusted to maintain total body weight at a constant level throughout the study period.
The following design was used for lipoprotein turnover studies. The studies required injections of exogenously labeled VLDL and LDL. Plasmapheresis was done 5 d before injection of labeled VLDL. VLDL was isolated by ultracentrifugation, labeled with 13'I, and prepared for injection. For 36 h before injection, the patients were fed a fat-free diet containing 60% of calories required for weight maintenance. They were then injected simultaneously with '31I-VLDL and [2-3H] glycerol. They were continued on the fat-free diet for another 48 h, and blood samples were obtained frequently during this period. On each plasma sample, total lipids were measured, and VLDL, IDL, and LDL were isolated by preparative ultracentrifugation. On whole plasma and each lipoprotein fraction, radioactivity was counted. Apo B was estimated on each lipoprotein fraction, and its specific activity was determined. Cholesterol and TG also were measured on each sample.
On the plasma obtained at plasmapheresis, LDL also was isolated by sequential centrifugation. LDL was iodinated with III, and prepared for injection. 48 h after injection of 13'I-VLDL, '25I-LDL was given intravenously. Blood samples were collected frequently during the 1st d after injection of '25I-LDL and then daily thereafter for 14 d. The diet for the period after injection of '25I-LDL was identical to that used before the study, i.e., an isocaloric diet containing 40% of calories as fat.
From masses and radioactivity data obtained above, multicompartmental analysis of lipoprotein kinetics was carried out as described in the preceding article (6 (13) .
Lipoprotein isolation and iodination for injection. After patients had been on the metabolic diet for 10-14 d, plasmapheresis was carried out by collecting blood (500 ml) into sterile, pyrogen-free bags containing 500 mg of disodium EDTA. After centrifugation (200C) at 5,500 g for 5 min, plasma was separated from cells, and the cells were returned to the patient. VLDL and LDL were isolated according to Lindgren et al. (14) . VLDL was separated at density (d) 1 .006 g/ml in an SW-27 swinging bucket rotor in an L2-65 B ultracentrifuge (Beckman Instruments, Inc., Spinco Div., Palo Alto, CA) at 23,000 rpm (10'C) for 22 h. VLDL was aspirated from the top by a Pasteur pipette, mixed with sterile NaCl solution (d 1.006 g/ml), and subjected to further ultracentrifugation for 22 h in a 40.3 Beckman rotor at 39,000 rpm (100C). The concentrated VLDL was then dialyzed against 0.15 M NaCI containing 0.01% EDTA (pH 7.4). After VLDL was removed after the first centrifugation, the infranatant was adjusted to d 1.025 g/ml with a sterile solution of NaCl-NaBr and centrifuged in a 60 Ti rotor at 59,000 rpm (15'C) for 18 h. After removal of the supernatant, the infranatant was adjusted to d 1.060 using NaCI-NaBr. LDL (16) . The molar ratio of iodine atoms and protein was less than one. The efficiency of radiolabeling of VLDL was 6-18% (mean 11%) and of LDL was 9-29% (mean 19%). The extent of lipid labeling was determined by extraction of the labeled VLDL and LDL with chloroform/methanol (2:1 vol/vol) (17). The organic phase was evaporated to dryness and radioactivity was determined in the residual lipid. The mean percentage of radioactivity in the lipid moiety of VLDL was 14% (range 8-29%) and in LDL was 4.5% (range 3-9%). The amount of unbound iodine after dialysis was determined by thin-layer chromatography on Gelman ITLC-SG sheets (Gelman Sciences, Inc., Ann Arbor, MI) using 20% trichloroacetic acid containing 0.125% sodium metabisulfite. The percentage of '"'I and 125I not bound to the VLDL (LDL) protein averaged 0.49% for VLDL and 0.35% for LDL.
After removal of unbound iodine by dialysis, the labeled lipoprotein preparation was subjected to centrifugation at 20,000 g for 30 min (4°C); the supernatant was removed and passed through a 0.22-,Rm Millipore filter (Millipore Corp., Bedford, MA). Sterile human serum albumin in a 5% solution was added to the '3'I-VLDL or 251I-LDL to dilute the final product to a concentration of -10 uCi/ml. This solution was then passed again through a 0.22-Am Millipore filter, and aliquots were tested for sterility and pyrogenicity.
Turnover design for VLDL-B and VLDL-TG. For 36 h before injection of radioactivity, the patients consumed a fat-free liquid formula every 3 h around the clock. The formula contained 1.25 cal/ g, 75% of which was glucose and 25% was milk protein. The liquid formula intake was calculated to provide 60% of the calories needed to maintain weight in the prestudy period. Fat was eliminated to prevent influx of chylomicrons during the study of VLDL metabolism. It was not replaced with carbohydrate to avoid carbohydrate-induced rise of plasma TG. This diet has been shown to be associated with a constant level of VLDL-TG throughout the 48-h study (18) . 4 d after plasmapheresis and after 36 h on the fat-free diet, patients were injected simultaneously with 1-6 mg of 13I-VLDL protein (5-25 sCi) and 300
MCi of [2-3H]glycerol (New England Nuclear, Boston, MA). Blood samples (10 ml) were collected at 0.25, 0.5, 1, 2, 3, 4, 5, 9, 12, 18, 24, 30, 36, 42, and 48 h after injection.
Turnover design for LDL-B. Immediately after the 48-h sample above, 2-10 mg of '25I-LDL protein ,Ci) were injected intravenously. The patients resumed the basic metabolic diet (described above). The first fat-containing meal was -3 h after the LDL injection.
Blood samples (10 ml) were collected at 0.25, 0. (20) . The value obtained by this procedure corresponded closely to the specific activity estimated by the difference between total mass and radioactivity and the soluble mass and radioactivity after TMU precipitation. For LDL specific activity, the total radioactivity and mass on an isolated fraction of LDL were determined. Apo B in this fraction was precipitated, and counts and peptide mass were determined on the supernatant. Apo B specific activity was then calculated by difference. 2 ml sample of plasma was also counted to determine 125I plasma activity.
VLDL-TG specific activity. The acetone and isopropanol extracts of VLDL samples were pooled for measurement of VLDL-TG specific activity. These extracts were evaporated to dryness with nitrogen at 60°C, and each dried residue was dissolved in 10 ml of isopropanol. Each sample was then treated with zeolite and isopropanol, and the supernatants were collected and transferred quantitatively into scintillation vials. These isopropanol extracts were dried under nitrogen at 60°C, and 10 ml of liquid flour was added to each vial. The samples were counted in a liquid scintillation counter (Mark II, Searle Radiographics Inc., Des Plaines, IL) for 3H-radioactivity after allowing enough time (usually over 2 mo) for complete '"'I decay. Concentrations of VLDL-TG were measured on each sample after isolation by ultracentrifugation.
Concentrations of lipoprotein lipid and apo B. The concentration of VLDL-B was determined as follows. The concentration of VLDL-TG was determined for each sample isolated by ultracentrifugation during the VLDL turnover study. The average concentration for the 48-h period was estimated using the correction for recovery described previously (21) . The lipids in IDL, LDL, and HDL were determined on each fraction isolated by successive ultracentrifugations. Percent recovery was estimated by comparing total cholesterol with the sum of cholesterol in all fractions. The final concentration of cholesterol and TG in each fraction was calculated by applying the same percent recovery to each.
For all VLDL samples, VLDL-B was determined as the difference between total protein and the TMU-soluble protein (19) . VLDL-B concentration was estimated by multiplying the corrected VLDL-TG concentration by the VLDL-B/TG ratio. Likewise, the IDL-B level was obtained by multiplying the IDL-B/TG ratio by the IDL-TG level.
The concentration of LDL-B used was that obtained during the VLDL-B turnover study. On the isolated LDL (d 1.019-1.063 g/ml), both LDL-cholesterol and LDL-B were measured; the apo B mass was calculated as the difference between total protein and TMU-soluble proteins (19) . The concentration of LDL-B was obtained by multiplying the corrected LDL-cholesterol by the LDL-B/TG ratio.
The pool size of apo B in each lipoprotein fraction was estimated as the product of the concentration times plasma volume. The plasma volume was determined by isotope dilution of labeled LDL. The concentration of injected label at 0 time was that obtained by extrapolation of to 0 of radioactivity in samples obtained over the first 20 min. This estimated plasma volume was used to determine plasma pool sizes of VLDL, IDL, and LDL.
Kinetic analysis
The data obtained in this study included concentrations of lipids (cholesterol and TG) and apo B in each lipoprotein fraction (VLDL, IDL, and LDL), specific activities of apo B in VLDL, IDL, and LDL, and urinary to plasma ratios for 125I (22). Multicompartmental analysis was carried out using the model shown in Fig. 7 of the preceding article (6) . This model allows the calculation of fractional catabolic rates (FCRs) and transport rates for VLDL-TG, total VLDL-B, IDL-B, and LDL-B. The fractions of VLDL-B passing through the chaindelipidation pathway and slowly catabolized compartment were determined, as were fractions of apo B transport through IDL-B. The proportion of VLDL-B removed directly from the circulation before conversion to IDL was estimated, as was the "direct" input of LDL. Finally, total input of apo B with lipoproteins was calculated from the model hypothesized in Fig. 10 of reference 6.
The results for transport rates are expressed as milligram/day, milligram/kilogram-day, and milligram/kilogram of IW-day for reasons described previously (18) . Statistical comparison of data among the groups was made with the Student's two-tailed t test.
Results
Concentrations of plasma cholesterol and TG, and cholesterol in LDL and HDL, during the VLDL turnover study are presented in Table II . There were no significant differences between mean values for normal subjects and either of the other two groups. However, one obese patient (no. 8) and one patient with CHD (no. 14) had abnormally high levels of LDL-cholesterol.
Data on VLDL-TG kinetics are given in Table III . Mean concentrations of VLDL-TG among the three groups were not significantly different. However, transport rates of VLDL-TG in the obese group, expressed as grams/day and milligrams/ kilogram of IW-day, were significantly higher than normal. In contrast, transport rates in the coronary group were not abnormally high.
Concentrations of VLDL-B were above normal in both obese and CHD patients (Table IV) . The FCRs of plasma VLDL-B, however, were not different among the groups. In obese patients, transport rates of VLDL-B were numerically but not statistically significantly higher than normal when expressed in absolute rates or per kilogram; they were nonetheless significantly higher when expressed per kilogram of IW. In CHD patients, transport rates of VLDL-B were higher than normal regardless of how data were expressed. The mean plasma VLDL-TG/VLDL-B ratio in normal subjects was 11.0±0.9; this value was not significantly different from that of obese patients (9.6±0.4), but it was significantly greater than that of CHD patients (6.9±0.3, P < 0.005). These differences in ratios reflect the finding that abnormally high transport rates were noted for both VLDL-TG and VLDL-B in obese subjects but only for VLDL-B, and not VLDL-TG, in CHD patients. These differences also are reflected in the ratios of transport rates for VLDL-TG and VLDL-apo B.
Data for IDL-B and LDL-B metabolism are presented in Tables V and VI for the three groups, and they were only 12-20% of those of VLDL-B. Turnover rates of IDL-B averaged about two pools per day which were somewhat slower than turnover of VLDL-B, but much greater than turnover of LDL-B (Table VI) . In none of the patients did transport rates of IDL-B through the plasma compartment equal the LDL-B transport.
Concentrations of LDL-B were similar on the average in the three groups, although the two patients (nos. 8 and 14) , who had elevated plasma LDL-C, also had relatively high levels of LDL-B. FCRs of LDL-B in normal subjects ranged from 0.31 to 0.38 pools/day, and they were not significantly different from the group means of either obese or CHI) patients. However, in three patients with CHD (nos. 11, 12, and 13), FCRs were greater than 0.43 pools/day. The two patients with abnormally high LDL-B levels (nos. 8 and 14) had relatively low FCRs. Two obese patients (nos. 8 and 9) had elevated transport rates of LDL-B (when data were expressed per kilogram of IW), but the other two (nos. 6 and 7) did not; transport rates for the whole group were not significantly different than normal. In contrast, patients with CHD had elevated rates of LDL-B transport whether data were normalized per kilogram or kilogram of IW.
For the determination of the fate of all apo B entering the system, transport rates and proportions of all pathways were computed on the basis of the model hypothesized in Fig. 10 of the preceding article (6) . Results are presented in Fig. 7 . Total input rates of apo B (-V0), expressed as milligram/day, were not significantly higher than normal in either obese or CHD patients; nonetheless, input rates were higher than normal in obese patients when data were normalized to ideal weight, and rates were abnormally high in CHD patients by normalization per kilogram of absolute weight or IW. Transfers between compartments are expressed as a percentage of all apo B entering V0. Most VLDL-B passed into the VLDL delipidation cascade (Via -a Vin). The proportion of VLDL-B converted to LDL through the delipidation chain (Via a V-n-LDL) was similar for normal, obese, and CHD patients (41+4%, 44+11%, and 33±10%, respectively). In normal subjects, direct removal of VLDL-B (V0 -out + V1, -out) averaged 27±7%. Although the percentages removed directly were numerically higher in obese patients (41±8%) and CHD patients (51±9%), they were not significantly different from normal. For most subjects of all groups, <5% of apo B passed through slowly catabolized VLDL (V2), whether V2-out or V2 -LDL. In all but one subject, at least a portion of apo-B mass in V0 was converted directly to LDL (V0 -LDL or "direct" input of LDL). In normal subjects, "direct" input of LDL averaged 28±5% of total input of apo B, and this percentage was significantly higher than that for either obese or CHD patients (10±3% and 15±1%, respectively).
Discussion
The primary aim of this study was to generate data for the development of a comprehensive and integrated model to describe the kinetics of apo B-containing lipoproteins, as presented in the preceding article (6) . A second purpose was to define and quantify pathways and compartments of these lipoproteins in normal subjects. For the latter purpose, tripleisotope studies were carried out in five normolipidemic men.
A third objective was to examine the metabolism of apo B in types of patients previously shown in our laboratory to have normal plasma lipids but increased turnover of LDL-B, namely, patients with obesity (four patients) and a group of patients with CHD (five patients). Although the numbers of subjects in each group were relatively small, the subjects seem representative of their categories based on data obtained previously in our laboratory (5, 6) . The parameters of lipoprotein kinetics determined in this investigation were generated by the multicompartmental analysis proposed in the preceding report (6) ; the validity of these parameters thus depends on the assumptions and limitations of this analysis.
Apo B metabolism in normal subjects. The five normal subjects of the current study had levels of plasma total cholesterol and TG in the normal range. Their transport rates of VLDL-TG were similar to those of a larger group of normal subjects studied previously (23) . For some reason, transport rates of LDL-B averaged 2-3 mg/kg-d higher than previously found for comparable normal subjects from our laboratory (4, 5); nonetheless, in most respects, this difference was not enough to obscure the differences between normal subjects and the two abnormal groups. Our findings in the normal subjects furthermore allow us to examine certain questions about the normal physiology of lipoproteins containing apo B.
First, let us ask how much apo B normally enters plasma each day with newly secreted lipoproteins. In our normal subjects, the total input of apo B averaged 19.6±1.7 mg/kg-d (Table VII) In the preceding article (6) , this untraced pathway was postulated to represent rapid catabolism of newly secreted VLDL, or possibly direct secretion of IDL. Untraced input of LDL-B was reported first in homozygous FH (28), but this route has been claimed more recently for other types of patients (34, 35) . In our current study, the normal subjects had a higher "direct" input of LDL-B than the other two groups who had overproduction of VLDL-B (Table VII For reasons not determined, the "direct" input of LDL also was relatively low in obese patient. Apo B metabolism in patients with CHD. We likewise have shown previously that a subset of patients with premature CHD have increased transport rates of LDL-B even in the absence of hypercholesterolemia (5) . Four of the five current patients with CHD also had normocholesterolemia; one patient (no. 14) had hypercholesterolemia, but he did not have tendon xanthomata or a family history suggestive of heterozygous FH. All patients in this group had relatively high transport rates of LDL-B. We therefore might ask about the mechanism responsible for an excessive input of LDL-B. Two possibilities can be considered: (a) increased fractional conversion of VLDL-B to LDL, as seemingly occurs when LDL receptor activity is low (24) , or (b) increased secretion of VLDL-B with a relatively normal fractional conversion of VLDL to LDL.
The current group of CHD patients clearly had increased secretion of VLDL-B. These patients had enhanced transport rates of VLDL-B even though the input of VLDL-TG was normal. They thus differed from our obese patients in whom secretion rates of both VLDL-TG and VLDL-B were high; the obese patients presumably secreted an increased number of normal VLDL in contrast to the CHD patients who apparently secreted an increased number of VLDL particles that were poor in TG.
The current patients with CHD confirms that overproduction of VLDL-B can occur without hyperlipidemia. Still, hyperlipidemia sometimes occurs in patients of this type. An increased synthesis of VLDL-B has been postulated as the underlying metabolic defect in familial combined hyperlipidemia (36) (37) (38) . We suggest that our patients, who also had overproduction of VLDL-B, had a similar if not identical metabolic defect. As suggested for obesity, an overproduction of lipoproteins on a primary basis theoretically might give rise to several different lipoprotein phenotypes. If the clearance capacity for lipoproteins is relatively high, concentrations will remain in the normal range, as seen in four of our patients with CHD. On the other hand, if concomitant abnormalities in catabolism are present, even though they may be relatively mild, various forms of hyperlipidemia will result. A concomitant defect in clearance of TG-rich lipoproteins thus may cause hypertriglyceridemia; this mechanism has been reported previously for patients with familial combined hyperlipidemia (23) . Furthermore, a decreased clearance capacity for LDL should cause a high concentration of LDL, as was noted in patient 14 who had both overproduction of VLDL-B and a low FCR of LDL-B.
The results should not be taken to mean that all patients with premature CHD have overproduction of VLDL-B; many of them probably do not (39) . The question must be raised whether the current patients' medications (i.e., f3-adrenergic blocking agents and diuretics) contributed to their abnormalities in apo B metabolism. This question is worthy of further investigation. Nonetheless, the observation remains that the current patients with CHD had overproduction of VLDL-B without excessive input of VLDL-TG, and this abnormality is in contrast to the combined overproduction of VLDL-B and VLDL-TG of obese patients (35) . Thus, a dissociation of secretion rates of VLDL-B and VLDL-TG can occur, and our findings raise the possibility that this pattern of VLDL secretion is associated with enhanced risk for CHD.
